# A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

> clinical trial · VERIFIED · 2026-08-28

Status: RECRUITING · Sponsor: NEOK Bio, Inc. · Condition: Locally Advanced (Unresectable) or Metastatic Solid Tumors

- Company: NEOK Bio, Inc.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07612176

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.